Who is sponsoring NCT04986345?

NCT04986345 is sponsored by Université de Sherbrooke.

What drugs are being tested in NCT04986345?

Interventions in NCT04986345: High-intensity interval training (HIIT)-4, High-intensity interval training (HIIT)-10, Rest.

What condition does NCT04986345 study?

NCT04986345 studies Diabetes Mellitus, Type 2.

Is NCT04986345 still recruiting?

NCT04986345 is currently status unknown. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT04986345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-intensity Interval Training Prescriptions to Reduce the Risk of Complications Linked to Type 2 Diabetes: the Role of Interval Length on Clinical Benefits and on Physiological Mechanisms

Status unknown NA Last updated 30 March 2023

What this trial tests

NA trial testing High-intensity interval training (HIIT)-4 in Diabetes Mellitus, Type 2 in 15 participants. Status unknown.

Timeline

4 October 2021

Primary endpoint
15 May 2023

31 August 2023

Quick facts

Lead sponsor	Université de Sherbrooke
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	15
Start date	4 October 2021
Primary completion	15 May 2023
Estimated completion	31 August 2023
Sites	1 location across Canada

Drugs / interventions tested

High-intensity interval training (HIIT)-4
High-intensity interval training (HIIT)-10
Rest

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Université de Sherbrooke — full company profile →

Who can join

Adults 60 to 80, female only, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 2 diabetes (T2D) prevalence has steadily been rising in the past decades and its complications, including cardiovascular diseases (CVD), are a major public health concern. To lower CVD risk and to maintain an adequate glycemic control, Diabetes Canada recommends aerobic exercise of high-intensity interval training (HIIT). The leading hypothesis of this study is that longer intervals will favor an anti-inflammatory immune state, and that and that it will be correlated with reduced arterial stiffness and blood pressure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An acute bout of 4 × 4-min or 10 × 1-min HIIT improves β cell glucose sensitivity in postmenopausal females with type 2 diabetes: a secondary analysis.
Low JL, Marcotte-Chénard A, Tremblay R, Islam H, et al · · 2025 · cited 2× · PMID 39694495 · DOI 10.1152/japplphysiol.00777.2024

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Université de Sherbrooke trials

Trials by the same sponsor.

NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04986345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing